1.. Introduction
================

Endometriosis is a condition defined as presence of endometrium outside of uterine cavity. It is very common, with an incidence of 5--20% among women in reproductive age, however, its causes still remain obscure. Numerous theories were proposed to explain etiology of endometriosis, reviewed well by Burney and Giudice ([@b1-mmr-18-03-3123]). Unfortunately, a single, sufficient explanation of disease causes is missing, since the origin seems to be connected with miscellaneous factors. It is widely accepted that underlying process leading to endometriosis development is retrograde menstruation, which is an antiperistaltic passage of menstrual debris through Fallopian tubes ([@b2-mmr-18-03-3123]). It has been proven though, that retrograde menstruation is a quite frequent phenomenon that occurs also in women without endometriosis ([@b3-mmr-18-03-3123]), therefore other factors must influence the stages of endometriosis development. The essential process in the disease onset is implantation of endometrial cells into peritoneal surface. Interestingly, during this process endometrial cells demonstrate some features of malignancy, as they are able to attach and to invade structure of peritoneum or ovary, in the similar way as cancer cells cause metastasis. This invasion is effectuated with matrix metalloproteinases (MMPs)-group of enzymes involved in tissue remodeling. This review is dedicated to the role of that group of enzymes and their inhibitors in development and pathogenesis of endometriosis.

2.. Matrix metalloproteinases and inhibitors of MMP
===================================================

Group of MMPs is a large family of endopeptidases, that are essential in degradation of extracellular matrix (ECM) and basal membrane (BM). Several subtypes of MMPs are distinguished, depending on their substrate-specificity and localization: Collagenases, gelatinases, stromelysins, matrilysins and membrane-type metalloproteinases. We summarize classification and substrate specificity of MMPs in [Table I](#tI-mmr-18-03-3123){ref-type="table"}, that was based on BRENDA-The Comprehensive Enzyme Information System database ([www.brenda-enzymes.org](www.brenda-enzymes.org)) ([@b4-mmr-18-03-3123]).

MMPs play a crucial role in numerous physiological processes, for instance: bone remodeling, angiogenesis, inflammation, ovulation and embryogenesis ([@b5-mmr-18-03-3123]). What is more, MMPs are involved in cyclic changes of endometrium structure and thickness in the course of endometrial cycle, feature that is caused by changes in steroid hormones concentration levels. MMPs are expressed in both epithelial and stromal cells, with the exception of MMP-7 that is detected selectively in epithelial compartment ([@b6-mmr-18-03-3123]). Furthermore, metalloproteinases present variable activity during the cycle, what was summarized in [Table II](#tII-mmr-18-03-3123){ref-type="table"} ([@b7-mmr-18-03-3123],[@b8-mmr-18-03-3123]).

Numerous MMPs are additionally involved in many pathological processes ([@b9-mmr-18-03-3123]), such as: fibrosis, weakening of matrix (e.g., in aortic aneurysm or dilated cardiomyopathy) or tissue destruction \[e.g., cancer invasiveness, also endometrial carcinoma invasiveness and ability to metastasize ([@b10-mmr-18-03-3123])\]. Therefore, the balance between activation and inhibition of MMPs is crucial for maintaining homeostasis. Their increased activity can cause excessive ECM degradation, while their deactivation-insufficient ECM remodeling. Both can lead to development of versatile medical conditions. Development of novel therapies, that would influence MMPs activity, seems to be promising but unreachable in short order.

The balance in MMPs activity is regulated by a very wide range of factors, which prevents accidental overactivation or suppression of MMPs and therefore help maintaining homeostasis. What is more, the number of known interactions is still growing.

3.. Regulation of MMP activity
==============================

One of the most important means of regulating MMPs activity are interactions with proteins, that inhibit final MMPs activity: Reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) ([@b11-mmr-18-03-3123]) and a group of soluble tissue inhibitor of metalloproteinases (TIMPs) ([@b12-mmr-18-03-3123]). These proteins significantly contribute in ECM remodeling, regulating angiogenesis and inflammatory reactions.

The mechanism of actions of TIMPs and RECK include formation of a stoichiometric complexes between inhibitor and a catalytic region of MMP. Binding blocks MMPs enzymatic activity. MMPs inhibitors are proteins, that have highly conservative sequence among species. Human genome encodes 4 genes coding TIMPs: TIMP1-TIMP4, that vary in substrate specificity ([@b13-mmr-18-03-3123]) ([Table III](#tIII-mmr-18-03-3123){ref-type="table"}).

Interestingly, TIMPs suppress the activity of not only MMPs, but also proteins from different family of endopeptidases, namely A Disintegrin And Metalloprotease family (ADAM) ([@b14-mmr-18-03-3123]--[@b17-mmr-18-03-3123]). ADAMs also fulfill similar functions in regulating inflammatory responses, cell migration and other aspects of matrix turnover ([@b18-mmr-18-03-3123]). The most active TIMP against ADAMs proteins is TIMP-3, while some other members of this family have only limited regulatory activity; for example, TIMP-1 inhibits ADAM-10 selectively ([@b17-mmr-18-03-3123]).

As summarized by Alexius-Lindgren ([@b19-mmr-18-03-3123]), RECK is membrane-bound MMPs inhibitor, especially active against MMP-9 ([@b11-mmr-18-03-3123]). RECK, similarly to soluble TIMPs, plays a crucial role in ECM remodeling and is involved with metastases and invasiveness of cancer ([@b20-mmr-18-03-3123]). Considering the common features between cancer metastases and endometriosis implants, RECK may be an interesting candidate gene to study in endometriosis development.

In addition to MMPs direct binding by inhibitors, their proteolytic activity is regulated also by cytokines, hormones, growth factors and many other biologically active agents ([@b21-mmr-18-03-3123]--[@b23-mmr-18-03-3123]). Steroid hormones were described as main agents, that have an influence on MMPs activity, especially in endometriosis and endometrial tissue turnover. Progestins are widely used in therapy of the disease, decreasing endometrial growth and endometriosis-associated pelvic pain ([@b24-mmr-18-03-3123]). They were proven to inhibit MMPs secretion by eutopic endometrial cells from uterine cavity ([@b25-mmr-18-03-3123]--[@b27-mmr-18-03-3123]) and ectopic lesions ([@b28-mmr-18-03-3123]), and to enhance TIMP-2 activity ([@b29-mmr-18-03-3123]). Similar effect was achieved by non-steroid progesterone receptor (PR) agonist ([@b30-mmr-18-03-3123]). Meanwhile, estrogenic stimulation was proven to induce MMP-2 and MMP-9 expression ([@b31-mmr-18-03-3123]). Moreover, there is a positive correlation between 17β-estradiol and MMP-2 serum levels in proliferative phase and a negative correlation between progesterone and MMP-2 serum levels in secretory phase of the cycle ([@b32-mmr-18-03-3123]).

Recent studies focus on non-steroid hormones, that could affect MMPs activity. It was shown, that numerous endocrine factors reduced ectopic lesions development in animal models of endometriosis. MMPs activity and endometrial fragment implantation can be regulated by: Leptin ([@b33-mmr-18-03-3123]), somatostatin ([@b34-mmr-18-03-3123]) and melatonin ([@b35-mmr-18-03-3123]). Discovery of such interactions is very promising, as alternative hormonal therapy in endometriosis would probably be less troublesome than hormonal suppression for patients in reproductive age. However, there are no clinical trials on their effectiveness in humans.

Other factors, that impact ECM remodeling by changing MMPs activity are immune system cells. Their role of uterine leukocyte population in endometriosis development was reviewed by Parkin and Fazleabas ([@b36-mmr-18-03-3123]).

Soluble agents, i.e., cytokines, such as TGF-β1, TNF-α and IFN-γ, IL-1, IL-4 and IL-8 regulate MMPs and TIMPs expression ([@b37-mmr-18-03-3123]--[@b39-mmr-18-03-3123]). IL-8, also known as neutrophil chemotactic factor, stimulates MMP-2 and MMP-9 expression in endometrium ([@b40-mmr-18-03-3123]). IL-1α enhances MMP-1 activity in human endometrial fibroblasts and endometrial cells ([@b27-mmr-18-03-3123],[@b41-mmr-18-03-3123]). Administration of IL-1α natural decoy-soluble form of IL-1 receptor type 2 (sIL-1R2), influences MMP-2, MMP-9 and TIMP-1, −2 and −3 activity in murine model of endometriosis, simultaneously affecting endometrial ability to invade and grow in ectopic locations ([@b42-mmr-18-03-3123]). On the other hand, administration of IL-4, an anti-inflammatory cytokine, inhibits MMP-3 and MMP-4 expression and reduces number and volume of ectopic lesions in murine model of endometriosis ([@b43-mmr-18-03-3123]). Besides cytokines, other immunological agents: eikosanoides, such as lipoxin A4 and prostaglandin E2, were also proven to alter MMP activity ([@b44-mmr-18-03-3123],[@b45-mmr-18-03-3123]).

Other regulators of MMPs and TIMPs activity are growth factors: EGF and FGF, that increase MMP-1, MMP-3, MMP-11 and TIMP-1 expression ([@b39-mmr-18-03-3123],[@b46-mmr-18-03-3123]). Retinoic acid inhibits MMP-3 and MMP-7 secretion ([@b47-mmr-18-03-3123]), and expression of extracellular matrix metalloproteinase inducer (EMMPRIN), a glycoprotein that was first discovered in tumor cells, which increases MMP-1 and MMP-2 expression ([@b48-mmr-18-03-3123]).

Factors presented above act simultaneously and affect each other. For example, Bruner *et al* reported, that progesterone requires TGF-β for its action and that progesterone and TGF-β cooperate in MMPs secretion inhibition ([@b49-mmr-18-03-3123]). Moreover, immunological impact on endometriosis development can be prevented by both steroid hormones or retinoic acid ([@b41-mmr-18-03-3123],[@b47-mmr-18-03-3123]). Those findings among others are an evidence, that no single factor is a master switch in MMPs and TIMPs regulations and subsequently in endometriosis etiology.

4.. MMP in menstrual effluent
=============================

As mentioned above, assumption of the pivotal role of retrograde menstruation is the most widely accepted theory explaining etiology of endometriosis. Studies performed *in vitro* showed, that endometrial cells can attach to intact peritoneum and invade through the mesothelium within 18--24 h ([@b50-mmr-18-03-3123]), concomitantly causing changes in morphology of the surface ([@b51-mmr-18-03-3123]). Those initial steps of ectopic lesions development require MMPs activity for basement membrane and ECM breakdown and subsequent invasion into the stroma. High levels of numerous MMPs in endometrium during menstruation ([@b7-mmr-18-03-3123],[@b52-mmr-18-03-3123]) and blockage of ectopic lesions formation in murine model of endometriosis after TIMP-1 intraperitoneal treatment ([@b53-mmr-18-03-3123]) are solid arguments for MMPs crucial role in endometriosis onset.

Noteworthy, the retrograde menstruation does not seem to be anomaly, as it is quite common and is observed both in women with and without endometriosis ([@b3-mmr-18-03-3123]). What is more, no difference was found in menstrual effluent volume and MMP-2 and MMP-9 levels in menstrual blood of women with endometriosis and in healthy control ([@b54-mmr-18-03-3123]). In conclusion, retrograde menstruation itself could be considered more as a condition and not as the only or main cause of ectopic endometrial lesions occurrence. Other molecular, genetic, hormonal and immunological factors could have significant contribution to disease development.

5.. MMP in peritoneal fluid
===========================

As retrograde menstruation is not sufficient to initiate ectopic lesions in peritoneum, the peritoneum has to provide a microenviroment for implant invasion. Numerous studies show altered cytokine levels and balance in peritoneal fluid collected from patients with endometriosis ([@b55-mmr-18-03-3123]--[@b57-mmr-18-03-3123]), and, as mentioned above, cytokines are potent regulators of MMPs activity. It remains undetermined, whether the imbalance is a cause and not a secondary result of ectopic lesions presence. Anyway, the immunological reactions ongoing in peritoneum may influence balance between MMPs and their inhibitors in endometriotic early implants and therefore augment endometriosis onset or further development. This theory is supported by the finding, that uterine endometrial cells cultivated in medium containing peritoneal fluid collected from women with endometriosis are characterized by MMP-2 overexpression ([@b58-mmr-18-03-3123]).

Peritoneal fluid collected from women with endometriosis shows elevated levels of MMPs and decreased levels of its inhibitors. MMP-2 ([@b32-mmr-18-03-3123]), MMP-3 ([@b59-mmr-18-03-3123]) and MMP-9 ([@b60-mmr-18-03-3123],[@b61-mmr-18-03-3123]) levels were significantly higher in peritoneal fluid of women with endometriosis than in healthy control, while TIMP-1 levels were lower ([@b61-mmr-18-03-3123]). However, no differences were found between the groups in TIMP-2 levels, and MMP-13 levels in peritoneal fluid were lower in women with endometriosis than in healthy control ([@b62-mmr-18-03-3123]).

Interestingly, although sex hormones are one of the most significant regulators of MMPs activity, no correlations between steroid hormones levels and MMP-9 ([@b61-mmr-18-03-3123]) and TIMP-1 ([@b63-mmr-18-03-3123]) activity in peritoneal fluid was found. This supports the theory, that there are the additional factors, that play a role in endometriosis early formation. However, once lesion appear, hormonal factors affect its growth and activity, causing cyclic changes and bleeding. Therefore hormonal treatment, that reduces the cyclic pattern and the level on endogenous hormones, is usually the first step in endometriosis management. Those relations have been proven by many studies. Among first findings on the issue is good to mention studies from 1990s, that showed reduction of hormone level in peritoneal fluid by gonadotropin-releasing hormone agonist (GnRH-a) in rat endometriosis model ([@b64-mmr-18-03-3123]). Moreover, in women with endometriosis treated with weak androgen danazol, TIMP-1 level in peritoneal fluid returned to normal ([@b63-mmr-18-03-3123]). Therefore, although hormonal factors have a questionable role in endometriosis onset, they clearly participate in its development.

6.. Changes of MMPs and TIMPs activity in eutopic endometrium
=============================================================

Studies revealing differences in MMPs and TIMPs activity in uterine endometrium collected from women with endometriosis and from healthy subjects, largely contributed to research on endometriosis. However, they do not fully clarify, whether MMPs or their inhibitors deregulation in eutopic endometrium is a primary pathology, that lead to disease development, or secondary reaction to ectopic lesions. Those abnormalities may also be secondary to occurrence of peritoneal lesions, which subsequently cause immunological or hormonal deregulation, that eventually influence uterine endometrium. Similar activity of MMPs in menstrual effluent of healthy and affected women militate for the first theory. Despite of the origins of the imbalance, although uterine endometrium from healthy women and women with endometriosis are structurally similar, wide range of biochemical and molecular differences are found between them ([@b65-mmr-18-03-3123]). Endometrium derived from women with endometriosis shows higher proteolytic activity than from healthy controls ([@b66-mmr-18-03-3123]). However, when comes to activity of specific MMPs and TIMPs in those two clinical groups, numerous opposing results were published. This may be caused by variability of MMPs activity during menstrual cycle or usage of different research methods, that present variable sensitivity and specificity for tested issues. For example, Colette *et al* found no statistically significant changes in MMP-9 level in uterine endometrium from study and control group, when tested by quantitative polymerase chain reaction (qPCR); however, the differences were significant, when using enzyme-linked immunosorbent assay (ELISA) or zymography ([@b67-mmr-18-03-3123]). Reports on these conflicting results are summarized in [Table IV](#tIV-mmr-18-03-3123){ref-type="table"} ([@b58-mmr-18-03-3123],[@b59-mmr-18-03-3123],[@b66-mmr-18-03-3123]--[@b78-mmr-18-03-3123]).

As presented in the [Table IV](#tIV-mmr-18-03-3123){ref-type="table"}, wide range of studies focused on MMP-2, −3, −9 and TIMP-1. Nevertheless, obtained results are unsettling, as even samples collected in one specific phase of the cycle and choosing the same method of measurement, gave totally non-reproducible outcomes. Partial explanation to this phenomenon could be various processes taking place in ectopic lesions, that would influence eutopic endometrium in a paracrine way. Newly formed lesions, with implantation process in progress, show different MMPs and TIMPs activity and cytokines levels than mature lesions with fibrosis and immune reaction on site. Therefore, uterine endometrium derived from women with endometriosis may show different MMPs and TIMPs activity, depending on ongoing processes in ectopic lesions and the disease stage.

7.. Activity of MMP in ectopic lesions
======================================

Numerous studies were performed to explain the relationships between MMPs levels in ectopic lesions and eutopic endometrium; similarly to results for uterine endometrium, it is quite common, that conflicting observations are reported. Those differences may be caused by wide range of reasons and could occur at any step of the study: choice of study group (e.g., different endometriosis stages or different phase of menstrual cycle), various types of ectopic lesions (e.g., peritoneal lesions, ovarian endometrioma wall fragments, endometrial tumors, pigmented or non-pigmented lesions), usage of different techniques (qPCR, western blotting and immunohistochemistry) or even different method of statistical analysis.

Endometriosis stage may affect results of MMPs assessment, as they are most active in early changes. Lu *et al* showed, that implantation of endometrium fragments in peritoneum in mouse model of endometriosis significantly increases MMP-2 level on site ([@b79-mmr-18-03-3123]). Similarly, in murine model of endometriosis performed by Sotnikova *et al*, MMP-2 levels were also the highest in early ectopic changes and decreased in time, while TIMP-2 levels were acting the opposite way-decreased after transplantation and gradually increased ([@b58-mmr-18-03-3123]). Moreover, in rat model of endometriosis, ectopic endometrial tissue showed higher expression of MMP-3 than uterine endometrium, and this relation was also the strongest in early lesions ([@b80-mmr-18-03-3123]). Ueda *et al* spotlighted, that MMPs levels may also differ in pigmented and non-pigmented ectopic lesions ([@b81-mmr-18-03-3123]). What is more, MMPs activity also differs in different types of ectopic lesions: retrovaginal, peritoneal or ovarian ([@b71-mmr-18-03-3123]). For example, MMP-1 is active in red peritoneal and ovarian lesions, and inactive in black peritoneal and retrovaginal lesions ([@b82-mmr-18-03-3123]) and MMP-27 is present in ovarian and peritoneal, but absent in retrovaginal lesions ([@b83-mmr-18-03-3123]).

As mentioned before, MMPs levels in uterine endometrium vary significantly througout menstrual cycle; Mizumoto *et al* showed, that it also applies to ectopic changes ([@b84-mmr-18-03-3123]). All that lead to a conclusion, that studies on MMPs especially on humans are very hard to conduct and to analyze, as high number of unrecognized factors may affect analysis of their outcomes.

All papers known to the authors, that compare MMPs and TIMPs levels in ectopic lesions and homologues eutopic endometrium are summarized in [Table V](#tV-mmr-18-03-3123){ref-type="table"} ([@b68-mmr-18-03-3123],[@b70-mmr-18-03-3123],[@b72-mmr-18-03-3123]--[@b78-mmr-18-03-3123],[@b85-mmr-18-03-3123]--[@b88-mmr-18-03-3123]). The results of previous studies are quite consistent when it comes to MMP-2 activity. Most of the studies spotlight higher activity of MMP-2 in ectopic lesions in comparison to uterine endometrium.

However, some studies use different type of control and investigate differences between MMPs and TIMPs activity in endometriotic lesions and uterine endometrium from healthy control \[summarized in [Table VI](#tVI-mmr-18-03-3123){ref-type="table"} ([@b58-mmr-18-03-3123],[@b73-mmr-18-03-3123],[@b75-mmr-18-03-3123],[@b76-mmr-18-03-3123],[@b81-mmr-18-03-3123],[@b83-mmr-18-03-3123],[@b89-mmr-18-03-3123],[@b90-mmr-18-03-3123])\]. This kind of analysis also seems to be informative in endometriosis research, since it compares 'most pathologic' with totally healthy tissue. In ectopic changes vs. homologous uterine endometrium analysis, the deregulation of MMPs-TIMPs balance is hard to see in ectopic lesions, as eutopic endometrium is also affected by the disease. What is more, in majority of those studies, no attention has been paid to phase of menstrual cycle during samples collection, which makes the results quite unreliable and straitened to analyze.

8.. Levels of MMP in serum
==========================

Endometriosis firm diagnosis requires laparoscopic surgery, which is an invasive procedure performed in general anesthesia. This is why numerous studies are conducted in order to find a sensitive and specific biomarker for endometriosis, that would allow the non-invasive diagnosis. Despite many attempts, no such protein or index based on a group of protein expression levels has been found so far, that would meet the terms of both: High sensitivity and high specificity ([@b91-mmr-18-03-3123]). MMPs and TIMPs activity in serum was also investigated and showed different levels in women with endometriosis than in healthy controls: MMP-2 and MMP-9 levels were higher ([@b32-mmr-18-03-3123],[@b60-mmr-18-03-3123]), and TIMP-1 levels lower ([@b63-mmr-18-03-3123]). However, none of them fulfill the requirements of a feasible biomarker for endometriosis diagnosis. Also no correlation was found between stage of endometriosis according to ASRM criteria and MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in serum ([@b92-mmr-18-03-3123]), although the results are dissonant, as Malvezzi *et al* found significantly higher levels of MMP-2 in serum of women with moderate to severe endometriosis compared to milder stages ([@b93-mmr-18-03-3123]).

9.. Polymorphism of MMPs genes in endometriosis
===============================================

Endometriosis seems to have some characteristics of genetic disease, but it certainly does not have a clear Mendelian inheritance pattern. The mechanisms of inheritance and a degree of influence of genetic background in endometriosis development are under discussion from decades ([@b94-mmr-18-03-3123]). Numerous studies were performed in order to find polymorphisms of genes, that are associated with the disease development. For example polymorphisms in the estrogen receptor ([@b95-mmr-18-03-3123]), TP53 ([@b96-mmr-18-03-3123]), or glutathione S-transferase M1 ([@b97-mmr-18-03-3123]) were proven to give predisposition to endometriosis. As MMPs seem to be important players in endometriosis occurrence and development, their genetics in the disease were also investigated ([@b98-mmr-18-03-3123]--[@b104-mmr-18-03-3123]). Those studies claim a correlation between single-nucleotide polymorphisms (SNPs) and haplotypes of MMP-2, MMP-7, MMP-9, MMP-12 and MMP-13, TIMP2 and endometriosis risk. Recently a few metaanalysises were published, summarizing those results. Two of them emphasize MMP-1 1607 1G/2G polymorphism in predicting endometriosis risk ([@b105-mmr-18-03-3123],[@b106-mmr-18-03-3123]). Nevertheless, no such correlation was found for MMP-2 15918 T/C (rs243847), MMP-2 −735 C/T (rs2285053), MMP-3 −1171 5A/6A, MMP-7 −181 A/G (rs11568818), MMP-9 −1562 C/T (rs3918242) and MMP-9 R279Q (rs17576) polymorphisms and endometriosis ([@b107-mmr-18-03-3123]). Obtained results require further studies, especially analysis of haplotypes, as they might be more predictive, then single SNPs.

10.. Future research and treatment perspectives
===============================================

Although since decades studies were conducted in order to explain endometriosis etiology, its causes still remain unknown. MMPs together with their inhibitors, as arrangement essential in ECM remodeling, attachment and invasion of endometrium into extrauterine surfaces, are without a doubt important players in the disease development. TIMPs play a protective role in the disease etiology, as proven by Bruner *et al* ([@b53-mmr-18-03-3123]). The presence and role of MMPs in endometriosis is unquestionable, however the exact sequence of events is unclear. It remains obscure, whether changes in their activity occur primarily in uterine cavity, that due to cellular memory allows endometrium fragments implantation into peritoneum, or whether specific conditions in peritoneal cavity (inflammation or other immunological processes) change MMPs activity in endometrial cells discarded from uterus during retrograde menstruation. Moreover, some balance switches in matrix remodeling in eutopic endometrium can be periodic or temporal and vanish just after lesion constitution on ectopic site. What is more, changes of MMPs and TIMPs activity, demonstrated in uterine endometrium from women with endometriosis may also occur after implantation of ectopic lesions, under the influence of processes taking place in peritoneum. Solution of this riddle seems to be hard to find, as it would require prospective study based on endometriotic biopsies in asymptomatic population of women and long-term observation for endometriosis onset. Taking into consideration the incidence rate of 1/1,000 per year, performance of such study on healthy population would by unfeasible and likely unethical. Furthermore, despite extensive research looking for endometriosis biomarkers, its proper diagnosis or clear exclusion still requires invasive procedure (laparoscopy), since many asymptomatic or conditionally symptomatic (subfertility) cases are present.

Except comparison of uterine endometrium from healthy control and women with endometriosis, numerous studies were also conducted in order to determine activity of MMPs and TIMPs in ectopic lesions (summarized in [Tables V](#tV-mmr-18-03-3123){ref-type="table"} and [VI](#tVI-mmr-18-03-3123){ref-type="table"}). These results are also unsettling, probably because of variable activity of MMPs and their inhibitors depending on numerous factors, such as phase of menstrual cycle or lesion type. In addition, the differences in research outcomes perfectly reflect variable role of MMPs in diverse steps of endometriosis development. Sotnikova *et al* showed, how activity of MMP-2 and TIMP-1 changes in ectopic lesions after their implantation in ectopic lesions in murine model of endometriosis, changing pattern from 'remodeling-favorable' during invasion to 'remodeling-limiting' after lesion formation ([@b58-mmr-18-03-3123]). Change of matrix turnover balance in peritoneal lesion, as well as reactive alteration of the balance in uterus, seems to be promising mechanisms not only for the disease onset but also for the explanation of pathological effects of the disease and symptom occurrence. Therefore, it becomes clear that experiments on human tissue, that are not collected in one, specific point of disease progression, will present unreliable results. As mentioned before, also every lesion type presents diverse results of MMPs and TIMPs activity ([@b71-mmr-18-03-3123],[@b81-mmr-18-03-3123]). Noteworthy, no correlation was found between American Society of Reproductive Medicine (ASRM) scores and MMPs and TIMPs levels in ovarian endometriomas ([@b108-mmr-18-03-3123]).

Interestingly, changes in MMP-TIMP balance, that occur periodically in menstrual cycle and in endometriosis formation, may not only be technical obstacle in performing studies on endometriosis, but also be an important key to understanding its pathogenesis. As it was described in [Table II](#tII-mmr-18-03-3123){ref-type="table"}, bimodal distribution of activity could be observed during physiological menstrual cycle. MMP are activated mainly in menstrual and in lower extend in proliferative phase of the cycle. TIMPs predominate especially in late secretory phase but TIMP-3 also in early menstrual phase. Similar domination of RECK in second part of the cycle was observed (authors\' unpublished data). It is undoubtful, that physiological interplay in regulation of endometrial matrix turnover would be responsible for endometrial growth in proliferative phase, endometrial stabilization in secretory phase, as well as endometrial break-down during menstruation and inhibition of endometrial implant formation in peritoneal cavity after menstruation. TIMP/RECK activation in secretory phase that persist in menstrual debris could be a potent protective mechanism. The inhibitory arm of the system is suppressed in eutopic endometrium in cases with endometriosis, so menstrual debris with lower TIMP expression could augment the implantation and lesion formation. It remains to be determined, which factors downregulate inhibitors of MMPs, because then some therapeutic or prophylactic intervention could be considered.

The role of matrix turnover in endometriosis is not unidirectional. As it was explained above, after the formation of endometrial lesions, the MMP-TIMP balance reverse to matrix stabilization by TIMP predominance ([@b58-mmr-18-03-3123]). On the one hand, the matrix remodeling inhibition can be an important protective reaction that prevents invasive growth of existing lesion and implantation of new endometrial fragments. On the other hand, impairment of normal matrix remodeling in peritoneal cavity is a proposed mechanism of ovulatory dysfunction (lutanized unruptured follicle-LUF syndrome), that could be a main cause of endometriosis related infertility. Overactivated TIMPs could reduce tissue break-down, that is necessary in ovulatory rupture. It was proven on animal model of endometrosis, that rats with endometriosis have increased TIMP-1 and unruptured follicle-like phenotype (LUF syndrome). Moreover, neutralization of TIMP-1 in these animals effectively restored ovulation and fertility ([@b109-mmr-18-03-3123],[@b110-mmr-18-03-3123]).

Recently an effective stimulation protocol dedicated to LUF syndrome was described for humans. In addition to standard ovarian stimulation, the single injection of G-CSF (granulocyte colony stimulating factor) in preovulatory period was administered, causing a significant reduction of LUF syndrome recurrence in comparison to standard ovarian stimulation alone. It is anticipated, that the most important effect of G-CSF in ovulation is leukocyte recruitment and activation in peritoneal cavity ([@b111-mmr-18-03-3123]). This activation of leukocytes leads to secretion of excessive amounts of MMPs and may overcome stoichiometric inhibition of TIMPs. Although this promising therapy is effective, low-cost and safe example of implementation of drug used before in other fields of medicine, further assessment of clinical effectiveness and clear explanation of molecular mechanism is necessary.

In conclusion, although over-activity of MMPs is one of the key pathologies, that lead to endometriosis occurrence, their excessive inhibition in later stages of the disease may have a deep influence on the endometriosis clinical picture. Implementation of novel treatment modalities that could change the ECM remodeling especially in periovulatory period in humans is promising. Selection between recombinant protein or small-molecule drugs with antagonistic or agonistic properties for MMP-TIMP system of interaction or their regulatory miRNA should be performed on basis of safety and clinical feasibility in practice. Therapeutic intervention has to be personalized and suited to the disease stage to shift the balance into correct direction.

To improve the research in future, every study that includes investigation of MMPs and TIMPs levels should include precise data: A phase of menstruation cycle during sample collection (preferably including sex hormones levels), ectopic lesion localization, its character and morphology. Nevertheless, some studies lack even the most basic information, which is menstrual cycle phase, or even compare the obtained results regardless of the cycle. It seems to distort the results and make collective analysis impossible, since activity of specific agents may differ remarkably between phases of menstrual cycle. On the other hand, certain studies present very complex and extended analysis, comparing obtained results to phase of the cycle and lesions type, such as Londero *et al* ([@b86-mmr-18-03-3123]) Including all the additional information about used samples seems to be essential for correct and conclusive analysis of results, that will later contribute to firmer understanding of MMPs and TIMPs role in endometriosis etiology. Moreover, collecting, processing and storage of the biological material should be performed with unified, standardized approach, such as proposed by World Endometriosis Research Foundation ([@b112-mmr-18-03-3123]).

RECK is an important player in maintaining balance between MMPs and their inhibitors. Although it is very widely investigated in other diseases (i.e., metastases, cancer invasion), research on its role in endometriosis is still sparse. It has been proven to have a pivotal role in many pathological conditions, as being a cellular membrane bound inhibitor closely resembles the activity of TIMPs. Therefore it seems to be necessary to complete previous knowledge of endometriosis and MMPs with studies on RECK.

Although the role of MMPs and their inhibitors in endometriosis etiology is indisputable, clinical usage of this knowledge is still doubtful at the moment. MMPs and their inhibitors regulate enormous number of both physiological and pathological processes. Therefore, any interference in the perfect balance between those agents may have severe consequences. Unfortunately no agents are known, that would work selectively on uterine endometrium or ectopic lesions, but some successful approaches in nonspecific shifting MMP-TIMP balance in periovulatory period were mentioned above ([@b111-mmr-18-03-3123]). Since TIMP, by down regulating MMP activity, also limits development of new ectopic lesions, usage of anti-MMPs agents may have a relevant impact on endometriosis prevention. The adverse effects of the therapy can by limited since the treatment could be periodic and selectively targeted to menstrual cycle. However, further studies are required, in order to clarify if inhibiting metalloproteinases and ECM remodeling would not only arrest occurrence of new lesions, but also limit progression of existing ones.
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###### 

Classification of MMPs.

  Enzyme    Aliases                                                                              Substrates in human
  --------- ------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  MMP-1     Interstitial collagenase, collagenase 1                                              Collagen I, II, III, casein, gelatin, α2-macroglobulin
  MMP-2     Gelatinase A, 72 kDa gelatinase, 72 kDa type IV collagenase                          Collagen I, IV, V, elastin, fibrilline, fibrinogen, fibronectin, galectin-3, gelatin, laminin, vitronectin
  MMP-3     Stromelysin 1, progelatinase                                                         Collagen I, IV, V, IX, X, α1-antitrypsin, α1-proteinase inhibitor, antithrombin III, casein, decorin, elastine, fibrillin, fibrin, fibronectin, gelatin, interleukin (IL)-1b, laminin, osteopontin, pro-MMP-1, tumor necrosis factor-α (TNF-α) precursor, Apaf-1, pro-caspase-9
  MMP-7     Matrilysin, PUMP-1, uterine metalloproteinase                                        Collagen IV, aggrecan, annexin II, β-casein, β4 integrin, connexin, E-cadherin, defensin, elastin, fibronectin, Fas-ligand, gelatin, insulin-like growth factor-binding protein-3 (IGFBP-3), laminin, nidogen, osteopontin, perlecan, plasminogen, tumor necrosis factor (TNF-α) precursor, syndecan, tenacin-C, tumor-associated antigen 90 K
  MMP-8     Neutrophil collagenase, PMNL collagenase                                             Collagen I, II, III, estrogen receptor α and β, TNF-α; serpins, bradykinin, angiotensin I, substance P
  MMP-9     Gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase                          Collagen I, III, IV, V, XI, actin, α-enolase, annexin I, crystallin, epidermal growth factor, ezrin, filamin B, galectin-3, gelatin, gelsollin, heat shock proteins, laminin, moesin, nucleolin, stathmin, stromelysin 1, tubulin, vitronectin
  MMP-10    Stromelysin-2, transin-2                                                             Collagen IV, V, IX, X, casein, elastin, fibrillin, fibronectin, gelatin, laminin, procollagenase (pro-MMP1)
  MMP-11    Stromelysin-3                                                                        Collagen IV, VI, IX, α1-antitrypsin, α1-protease inhibitor, casein, elastin, fibronectin, insulin-like growth factor-binding protein-1 (IGFBP-1), laminin
  MMP-12    Metalloelastase, macrophage metalloelastase, macrophage elastase                     Collagen I, III, IV, α1-antitrypsin, β-casein, elastin, enactin, fibronectin, gelatin, laminin, plazminogen, TNF-α, vitronectin
  MMP-13    Collagenase 3                                                                        Collagen I, II, III, IV, VI, IX, \'X, XIV, α2-macroglobullin, antichymotrypsin, β-casein, decorin, factor XII, fibrillin, fibrinogen, fibronectin, gelatin, laminin, plasminogen activator inhibitor, serglycin, TIMP1, transforming growth factor β (TGF-β), xylosyltransferase 1
  MMP-14    Membrane type-1-matrix metalloproteinase (MT1-MMP)                                   Collagen I, II, III, α-1 microglobulin, α-2 macroglobulin, α-2-HS-glycoprotein, α1-antitrypsin, α1-proteinase inhibitor, α5 integrin, apolipoprotein A, apolipoprotein E and apolipoprotein J, brain-specific angiogenesis inhibitor 1, casein, CD44, fibrin II, E-cadherin, elastin, endoglin, entactin, epidermal growth factor receptor, extracellular matrix metalloproteinase inducer, gelatin, fibrillin, fibrin, fibrinogen, fibroblast growth factor recetor (FGFR) 1 and 4, fibronectin, galectin-3, gelsolin, growth differentiation factor-1, heparin-binding epidermal growth factor, hepatocyte growth factor activator inhibitor-1, inter-α inhibitor H4, intercellular cell adhesion molecule-1, kidney injury molecule-1, Kisspeptin/metastin, laminin, mannose-binding lectin, mucin 1, N-cadherin, Notch1, pro-MMP-2, −8 and −13, pro-transforming growth factor β, progelatinase A, receptor-activator of NF-kB ligand, stromal cell-derived factor 1, testican-1, transforming growth factor-β, transglutaminase, vitronectin
  MMP-15    Membrane type-2 matrix metalloproteinase (MT2-MMP, MTMMP2)                           Weak collagenase activity; cell surface tissue transglutaminase, fibronectin, laminin, pro-MMP-2 and −13, tenascin
  MMP-16    MT3-MMP, MTMM3                                                                       Collagen III, casein, fibronectin, gelatin, pro-MMP-2
  MMP-17    MT4-MMP, MTMM4                                                                       MT4-MMP acts as a TNF-α-converting enzyme, and as a glycosylphosphatidylinositol-anchored enzyme
  MMP-19    RASI-1 MMP-18 (precursor of MMP-19)                                                  Very limited activity versus gelatin; tenascin C
  MMP-20    Enamelysin, enamel metalloproteinase                                                 Collagen V, amelogenin, enamel protein, endostatin
  MMP-21    HTX7                                                                                 α1-proteinase inhibitor
  MMP-23B   Femalysin, matrix metalloproteinase in the female reproductive tract, MIFR, MIFR-1   
  MMP-24    MT5-MMP-5, MTMMP5                                                                    Gelatin, fibronectin, pro-MMP-2
  MMP-25    MT6-MMP, MMP-20, MMPL1                                                               Collagen IV, α1-proteinase inhibitor, fibrin, fibronectin, gelatin, pro-MMP-2
  MMP-26    Matrilysin-2, endometase                                                             Collagen IV, α1-antitrypsin, α2-macroglobulin, fibronectin, fibrinogen, insulin-like growth factor-binding protein 1 (IGFBP-1), plazminogen, pro-MMP-9, vitronectin
  MMP-27    --                                                                                   Casein, gelatin
  MMP-28    Epilysin                                                                             Casein, NCAM

Examples of their substrates. Source: BRENDA-The Comprehensive Enzyme Information System ([@b4-mmr-18-03-3123]).

###### 

Relative expression of various MMPs and TIMPs through the menstrual cycle.

           Menstrual cycle phase                                    
  -------- ----------------------- ------ ------ ------ ------ ---- ------
  MMP-1    ++++                    ++++   \+     \+     \+     \+   \+
  MMP-2    +++                     +++    ++     ++     ++     ++   ++
  MMP-3    ++++                    ++++   \+     \+     \+     \+   \+
  MMP-7    ++++                    ++++   ++++   ++++   \+     \+   \+
  MMP-8    ++++                    ++     \+     \+     \+     \+   \+
  MMP-9    ++                      ++     \+     \+     \+     \+   \+
  MMP-10   ++++                    ++++   ++     ++     \+     ++   ++
  MMP-11   ++++                    ++++   ++++   ++++   \+     \+   \+
  MMP-12   ++++                    \+     \+     \+     \+     \+   \+
  MMP-14   +++                     +++    ++     ++     ++     ++   ++
  MMP-15   ++                      ++     ++     ++     ++     ++   ++
  MMP-16   \+                      \+     ++     ++     ++     \+   \+
  MMP-19   ++                      ++     ++     ++     ++     ++   ++
  MMP-26   \+                      \+     ++     ++     ++++   ++   \+
  TIMP-1   ++                      ++     ++     ++     ++     ++   ++
  TIMP-2   ++                      ++     ++     ++     ++     ++   ++
  TIMP-3   ++++                    ++     ++     ++     ++     ++   ++++
  TIMP-4   \+                      \+     \+     ++     ++++   ++   \+

Minimal expression, +; Strong expression, ++++; and Moderate expression, ++ and +++. MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metallopeptidase.

###### 

Characterization of substrate specificity of TIMPs.

  Variable                   TIMP-1                                               TIMP-2                                                           TIMP-3                                                           TIMP-4
  -------------------------- ---------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ----------------
  Activity against           Membrane-type MMPs                                   Very wide activity                                               Very wide activity                                               Active against
  MMPs                       (MT1-, MT3-, MT5-MMP) MMP-19                         (weaker inhibition of MMP-3 and MMP-7 in comparison to TIMP-1)   (weaker inhibition of MMP-3 and MMP-7 in comparison to TIMP-1)   most MMPs
  Activity against           ADAM-10                                              ADAM-12                                                          ADAM-10, −12, −17, −28 −33,                                      ADAM-17, −28
  ADAMs                                                                                                                                            ADAMTSs                                                          
  Other functions            EPA-erythroid-potentiating activity Anti-apoptotic   EPA-erythroid-potentiating activity Anti-apoptotic               Inhibits angiogenesis Pro-apoptotic                              
  Interaction with pro-MMP   Pro-MMP-9                                            Pro-MMP-2                                                        Pro-MMP-2 Pro-MMP-9                                              Pro-MMP-2

MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metallopeptidases.

###### 

Alterations in MMP\'s/TIMP\'s expression in eutopic endometrium in endometriosis vs. control endometrium.^[a](#tfn4-mmr-18-03-3123){ref-type="table-fn"}^

  First author, year        MMP-no.   Obtained result                         Method used and phase of menstrual cycle           (Refs.)
  ------------------------- --------- --------------------------------------- -------------------------------------------------- -------------------------
  Di Carlo, 2009            MMP-1     Increased in women with endometriosis   qPCR, IHC, secretory                               ([@b68-mmr-18-03-3123])
  Collette, 2004            MMP-2     No difference                           Zymography, ELISA; in cell culture                 ([@b66-mmr-18-03-3123])
  Di Carlo, 2009                                                              IHC, secretory                                     ([@b68-mmr-18-03-3123])
  Szymanowski, 2016                                                           qPCR, secretory                                    ([@b69-mmr-18-03-3123])
  Wenzl, 1998                                                                 IHC, results evaluated irrespective of the phase   ([@b70-mmr-18-03-3123])
  Uzan, 2004                                                                  IHC, whole cycle                                   ([@b71-mmr-18-03-3123])
  Sotnikova, 2010                     Increased in women with endometriosis   qPCR, PNS                                          ([@b58-mmr-18-03-3123])
  Di Carlo, 2009                                                              qPCR, secretory                                    ([@b68-mmr-18-03-3123])
  Chung, 2002                                                                 qPCR and zymography, whole cycle                   ([@b72-mmr-18-03-3123])
  Gilabert-Estellés, 2007   MMP-3     No difference                           qPCR and ELISA, proliferative                      ([@b59-mmr-18-03-3123])
  Gilabert-Estellés, 2007             Increased in women with endometriosis   qPCR and ELISA, secretory                          ([@b59-mmr-18-03-3123])
  Gilabert-Estellés, 2003                                                     qPCR, whole cycle                                  ([@b73-mmr-18-03-3123])
  Ramón, 2005                                                                 qPCR, ELISA, PNS                                   ([@b74-mmr-18-03-3123])
  Uzan, 2004                          Decreased in women with endometriosis   IHC, whole cycle                                   ([@b71-mmr-18-03-3123])
  Collette, 2006            MMP-9     No difference                           qPCR, PNS                                          ([@b67-mmr-18-03-3123])
  Szymanowski, 2016                                                           qPCR, secretory                                    ([@b69-mmr-18-03-3123])
  Chung, 2001                                                                 qPCR, whole cycle                                  ([@b75-mmr-18-03-3123])
  Collette, 2004                      Increased in women with endometriosis   Zymography, ELISA; in cell culture                 ([@b66-mmr-18-03-3123])
  Collette, 2006                                                              Zymography, ELISA, PNS                             ([@b67-mmr-18-03-3123])
  Di Carlo, 2009                                                              qPCR, IHC, secretory                               ([@b68-mmr-18-03-3123])
  Pan, 2008                                                                   Western blotting, whole cycle                      ([@b76-mmr-18-03-3123])
  Uzan, 2004                MMP-11    Decreased in women with endometriosis   IHC, whole cycle                                   ([@b71-mmr-18-03-3123])
  Chung, 2002               MT1-MMP   Increased in women with endometriosis   qPCR, secretory phase                              ([@b72-mmr-18-03-3123])
  Gaetje, 2007              MT5-MMP   Increased in women with endometriosis   qPCR, PNS                                          ([@b77-mmr-18-03-3123])
  Gilabert-Estellés, 2007   TIMP-1    No difference                           qPCR and ELISA, proliferative; qPCR secretory      ([@b59-mmr-18-03-3123])
  Collette, 2004                                                              ELISA, proliferative                               ([@b66-mmr-18-03-3123])
  Collette, 2006                                                              qPCR and ELISA, PNS                                ([@b67-mmr-18-03-3123])
  Szymanowski, 2016                                                           qPCR, secretory                                    ([@b69-mmr-18-03-3123])
  Gilabert-Estellés, 2003                                                     ELISA, whole cycle                                 ([@b73-mmr-18-03-3123])
  Laudanski, 2014                                                             Western blotting, ELISA, proliferative             ([@b78-mmr-18-03-3123])
  Gilabert-Estellés, 2007             Increased in women with endometriosis   ELISA, secretory                                   ([@b59-mmr-18-03-3123])
  Laudanski, 2014                                                             qPCR, proliferative                                ([@b78-mmr-18-03-3123])
  Collette, 2004                      Decreased in women with endometriosis   ELISA, secretory                                   ([@b66-mmr-18-03-3123])
  Sotnikova, 2004           TIMP-2    Increased in women with endometriosis   qPCR, PNS                                          ([@b58-mmr-18-03-3123])
  Chung, 2002                         Decreased in women with endometriosis   qPCR, proliferative                                ([@b72-mmr-18-03-3123])
  Chung, 2001               TIMP-3    No difference                           qPCR, proliferative                                ([@b75-mmr-18-03-3123])
  Chung, 2001                         Decreased in women with endometriosis   qPCR, secretory                                    ([@b75-mmr-18-03-3123])

Summary of literature comprising used method and phase of menstrual cycle. qPCR, quantitative polymerase chain reaction; IHC, immunohistochemistry; ELISA, enzyme-linked immunosorbent assay. Proliferative/secretory/whole cycle refers to phases of menstrual cycle. PNS, menstrual phase not specified.

###### 

Alterations in MMP\'s/TIMP\'s expression in ectopic lesions vs. autologus eutopic endometrium.^[a](#tfn5-mmr-18-03-3123){ref-type="table-fn"}^

  First author, year        MMP-no.   Obtained result                  Method used and phase of menstrual cycle           (Refs.)
  ------------------------- --------- -------------------------------- -------------------------------------------------- -------------------------
  Di Carlo, 2009            MMP-1     Higher in ectopic than eutopic   IHC, qPCR, secretory phase                         ([@b68-mmr-18-03-3123])
  Shaco-Levy, 2008          MMP-2     No difference                    IHC, proliferative                                 ([@b85-mmr-18-03-3123])
  Di Carlo, 2009                      Higher in ectopic than eutopic   IHC, qPCR, secretory                               ([@b68-mmr-18-03-3123])
  Wenzl, 1998                                                          IHC, results evaluated irrespective of the phase   ([@b70-mmr-18-03-3123])
  Londero, 2012                                                        IHC, whole cycle                                   ([@b86-mmr-18-03-3123])
  Chung, 2002                         Lower in ectopic than eutopic    qPCR, proliferative                                ([@b72-mmr-18-03-3123])
  Gilabert-Estellés, 2003   MMP-3     Lower in ectopic than eutopic    ELISA, PNS                                         ([@b73-mmr-18-03-3123])
  Meola, 2010                                                          qPCR, proliferative                                ([@b87-mmr-18-03-3123])
  Di Carlo, 2009            MMP-9     No difference                    IHC, secretory                                     ([@b68-mmr-18-03-3123])
  Chung, 2001                                                          qPCR, proliferative                                ([@b75-mmr-18-03-3123])
  Pan, 2008                                                            Western blotting, whole cycle                      ([@b76-mmr-18-03-3123])
  Di Carlo, 2009                      Higher in ectopic than eutopic   qPCR, secretory                                    ([@b68-mmr-18-03-3123])
  Chung, 2001                                                          qPCR, secretory                                    ([@b75-mmr-18-03-3123])
  Shaco-Levy, 2008                                                     IHC, proliferative                                 ([@b85-mmr-18-03-3123])
  Liu, 2002                                                            Zymography, PNS                                    ([@b88-mmr-18-03-3123])
  Chung, 2002               MT1-MMP   No difference                    qPCR, proliferative                                ([@b72-mmr-18-03-3123])
  Londero, 2012                       Higher in ectopic than eutopic   IHC, whole cycle                                   ([@b86-mmr-18-03-3123])
  Chung, 2002                         Lower in ectopic than eutopic    qPCR, secretory                                    ([@b72-mmr-18-03-3123])
  Gaetje, 2007              MT5-MMP   Higher in ectopic than eutopic   qPCR, PNS                                          ([@b77-mmr-18-03-3123])
  Gilabert-Estellés, 2003   TIMP-1    Higher in ectopic than eutopic   ELISA, PNS                                         ([@b73-mmr-18-03-3123])
  Ramón, 2005                                                          qPCR, ELISA, PNS                                   ([@b74-mmr-18-03-3123])
  Londero, 2012             TIMP-2    Higher in ectopic than eutopic   IHC, whole cycle                                   ([@b86-mmr-18-03-3123])
  Laudanski, 2014                     Lower in ectopic than eutopic    qPCR, proliferative                                ([@b78-mmr-18-03-3123])
  Chung, 2001               TIMP-3    No difference                    qPCR, whole cycle                                  ([@b75-mmr-18-03-3123])

Summary of literature comprising used method and phase of menstrual cycle. qPCR, quantitative polymerase chain reaction; IHC, immunohistochemistry; ELISA, enzyme-linked immunosorbent assay. Proliferative/secretory/whole cycle refers to phases of menstrual cycle. PNS, menstrual phase not specified.

###### 

Alterations in level of MMP\'s/TIMP\'s in ectopic lesion in relation to control endometrium.^[a](#tfn6-mmr-18-03-3123){ref-type="table-fn"}^

  First author, year        MMP-no.   Obtained result                                      Method used and phase of menstrual cycle               (Refs.)
  ------------------------- --------- ---------------------------------------------------- ------------------------------------------------------ -------------------------
  Gottschalk, 2000          MMP-1     Higher in ectopic lesion than healthy control        IHC, PNS                                               ([@b89-mmr-18-03-3123])
  Gottschalk, 2000          MMP-2     No difference                                        IHC, PNS                                               ([@b89-mmr-18-03-3123])
  Sotnikova, 2010                     Higher in ectopic lesion than healthy control:       qPCR, PNS                                              ([@b58-mmr-18-03-3123])
  Ueda, 2002                                                                               qPCR, PNS                                              ([@b81-mmr-18-03-3123])
  Ria, 2002                                                                                *In situ* hybridization, PNS                           ([@b90-mmr-18-03-3123])
  Gottschalk, 2000          MMP-3     No difference                                        IHC, PNS                                               ([@b89-mmr-18-03-3123])
  Gilabert-Estellés, 2003                                                                  ELISA, PNS                                             ([@b73-mmr-18-03-3123])
  Gottschalk, 2000          MMP-9     No difference                                        IHC, PNS                                               ([@b89-mmr-18-03-3123])
  Pan, 2008                           Higher in ectopic lesion than healthy control:       Western blotting, whole cycle                          ([@b76-mmr-18-03-3123])
  Ueda, 2002                                                                               qPCR, PNS                                              ([@b81-mmr-18-03-3123])
  Ria, 2002                                                                                *In situ* hybridization, PNS                           ([@b90-mmr-18-03-3123])
  Cominelli, 2014           MMP-27    Higher in ectopic lesion than healthy control        qPCR, PNS; one-tailed Wilcoxon signed rank test only   ([@b83-mmr-18-03-3123])
  Ueda, 2002                MT1-MMP   Higher in ectopic lesion than healthy control        qPCR, PNS                                              ([@b81-mmr-18-03-3123])
  Gilabert-Estellés, 2003   TIMP-1    Higher in ectopic lesion than healthy control        ELISA, PNS                                             ([@b73-mmr-18-03-3123])
  Sotnikova, 2010           TIMP-2    No difference                                        qPCR, PNS                                              ([@b58-mmr-18-03-3123])
  Chung, 2001               TIMP-3    No difference                                        qPCR, proliferative                                    ([@b75-mmr-18-03-3123])
  Chung, 2001                         Lower in ectopic endometrium than healthy control:   qPCR, secretory                                        ([@b75-mmr-18-03-3123])

Summary of literature comprising used method and phase of menstrual cycle. qPCR, quantitative polymerase chain reaction; IHC, immunohistochemistry; ELISA, enzyme-linked immunosorbent assay. Proliferative/secretory/whole cycle refers to phases of menstrual cycle. PNS, menstrual phase not specified.
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